According to the latest market study by Future Market Insights, the global ioversol market is projected to achieve a valuation of US$ 467.5 million in 2022, with a forecasted compound annual growth rate (CAGR) of 7.0% from 2022 to 2032. Ioversol, a contrast medium commonly used in medical imaging procedures, is anticipated to experience significant market expansion during this period. Factors such as increasing diagnostic imaging procedures and the rising prevalence of various medical conditions are expected to drive the sustained growth of the Ioversol market, making it a key player in the healthcare sector.
Ioversol is primarily utilized as a contrast medium in radiographic examinations, particularly in CT scans. It is injected into the body to highlight blood vessels, organs, and other tissues, allowing for a clearer and more detailed view of the internal structures.
Request Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-2287
The demand for contrast agents like Ioversol is influenced by the increasing prevalence of diagnostic imaging procedures. The growing incidence of chronic diseases, such as cardiovascular disorders and cancer, has led to a rise in the number of imaging studies, thereby contributing to the growth of the contrast media market.
Competitive Landscape:
The market for contrast agents is competitive, with several pharmaceutical companies manufacturing and distributing Ioversol. Companies may focus on research and development to improve formulations, reduce side effects, and enhance overall safety and efficacy.
Key Companies Profiled
- Liebel-Flarsheim Company LLC
- Guerbet
- Jiangsu Hengrui Medicine Co.
- Mallinckrodt Pharmaceuticals
- Ultraject
- China Resources Pharmaceutical Co.
- HB Ocean
- Changzhou Highassay Chemical Co., Ltd.
- Novalek Pharmaceuticals Pvt. Ltd
- Stellence Pharmscience Pvt. Ltd.
- A.S. Joshi & Company
Contact Sales for Further Assistance in Purchasing this Report: https://www.futuremarketinsights.com/checkout/2287
Ioversol Market Segmentation
By Type
- Ioversol 34% Injectable Solution (Optiray 160)
- Ioversol 51% Injectable Solution (Optiray 240)
- Ioversol 64% Injectable Solution (Optiray 300)
- Ioversol 68% Injectable Solution (Optiray 320)
- Ioversol 74% Injectable Solution (Optiray 350)
By Packaging
- Vials
- Bottles
- Hand-Held Syringes
- Power Injector Syringes
By Application
- X-ray
- CT scan
- Radiological & Diagnostic Examinations
- Angiography
- Urography
- Computed Tomographic Scans
- Others.
By Region
- North America
- Latin America
- Europe
- South Asia Pacific
- East Asia
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube